{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee Y"],"funding":["Ministry of Science, ICT and Future Planning","National Research Foundation of Korea"],"pagination":["249-260"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10658310"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["53"],"pubmed_abstract":["<h4>Introduction</h4>miRNA-21 (miR-21) is highly expressed in glioblastoma, facilitating tumor growth by blocking the expression of apoptosis-related genes. Therefore, an antisense microRNA oligonucleotide (AMO) against miR-21 was suggested as a therapeutic nucleic acid for glioblastoma.<h4>Objectives</h4>AMO21 co-micelles were developed with tumor-targeting T7 peptides as an AMO21 delivery system by intranasal administration.<h4>Methods</h4>Cholesterol-conjugated AMO21 (AMO21c) was mixed with cholesterol-conjugated T7 peptides (T7c) to produce tumor-targeted co-micelles. Physical characterization was performed by dynamic light scattering, gel retardation assay, scanning electron microscope and heparin competition assay. In vitro transfection efficiency to C6 glioblastoma cells was measure"],"journal":["Journal of advanced research"],"pubmed_title":["Antisense-oligonucleotide co-micelles with tumor targeting peptides elicit therapeutic effects by inhibiting microRNA-21 in the glioblastoma animal models."],"pmcid":["PMC10658310"],"funding_grant_id":["2022R1A2B5B01001920"],"pubmed_authors":["Ha J","Kang S","Lee M","Kang M","Lee Y","Kim M"],"additional_accession":[]},"is_claimable":false,"name":"Antisense-oligonucleotide co-micelles with tumor targeting peptides elicit therapeutic effects by inhibiting microRNA-21 in the glioblastoma animal models.","description":"<h4>Introduction</h4>miRNA-21 (miR-21) is highly expressed in glioblastoma, facilitating tumor growth by blocking the expression of apoptosis-related genes. Therefore, an antisense microRNA oligonucleotide (AMO) against miR-21 was suggested as a therapeutic nucleic acid for glioblastoma.<h4>Objectives</h4>AMO21 co-micelles were developed with tumor-targeting T7 peptides as an AMO21 delivery system by intranasal administration.<h4>Methods</h4>Cholesterol-conjugated AMO21 (AMO21c) was mixed with cholesterol-conjugated T7 peptides (T7c) to produce tumor-targeted co-micelles. Physical characterization was performed by dynamic light scattering, gel retardation assay, scanning electron microscope and heparin competition assay. In vitro transfection efficiency to C6 glioblastoma cells was measure","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2025-04-22T09:27:08.434Z","creation":"2025-04-05T23:03:08.93Z"},"accession":"S-EPMC10658310","cross_references":{"pubmed":["36632887"],"doi":["10.1016/j.jare.2023.01.005"]}}